pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
To evaluate the pharmacokinetics and safety of nolasiban
Phase 1 · other · not applicable (submitted trial is a pharmacokinetic study in healthy subjects)
To evaluate the pharmacokinetics and safety of nolasiban for not applicable (submitted trial is a pharmacokinetic study in healthy subjects) is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code RPN-NLS01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Modality
- other
- Indication
- not applicable (submitted trial is a pharmacokinetic study in healthy subjects)
- Status
- active
- Trials
- 1